<DOC>
	<DOCNO>NCT02041091</DOCNO>
	<brief_summary>The purpose study evaluate amount tabalumab blood give two different injection method - A traditional syringe spring load syringe 12 week . Participants may continue receive study drug 52 week .</brief_summary>
	<brief_title>A Study Tabalumab ( LY2127399 ) Using Two Different Injection Methods Participants With Lupus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis Lupus . Able willing blood drawn PK sampling . Have severe active lupus nephritis . Have severe active central nervous system ( CNS ) peripheral neurologic disease severe neurologic involvement require treatment within approximately 3 month prior screen . Have receive high dose corticosteroid within approximately 1 month prior baseline . Have initiate adjust treatment immunosuppressant drug within approximately 1 month prior baseline . Have receive plasmapheresis within approximately 3 month prior baseline . Have previously receive approved experimental B cell target therapy within last year . Have receive biologic nonbiologic therapy within approximately 3 month 5 halflives ( whichever longer ) . Have history severe reaction biologic therapy . Have active recent infection within approximately 1 month prior Week 0 . Have serious infection within approximately 3 month serious bone/joint infection within approximately 6 month prior baseline . Have evidence test positive active hepatitis B positive hepatitis C human immunodeficiency virus ( HIV ) . Have evidence active latent tuberculosis . Have significant hematological abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>